Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.39 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: selurampanel, talampanel, tezampanel +11 | 1.00 |
| trials ClinicalTrials.gov | 3 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 9 Parkinson's papers of 347 | 0.70 |
| pathways Reactome | 8 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 0669
Sealed predictions
- GRIA1 in dopamine neurons, braak-0.20 (p 0.598) → -0.07 (p 0.855)receipt 0676
Swarm cases
receipt 0676: GRIA1 in dopamine neurons, braak
- power
- full sample -0.05 (p 0.857, n 18), 95% CI -0.50 to +0.43. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.05 (p 0.857, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.01 (p 0.983, n 18). could be the mix.
- skeptic
- leave-one-out range -0.16 to +0.08, sign flips 4; without severely affected donors -0.05 (p 0.857, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GRIA1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts